Filtered By:
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 210 results found since Jan 2013.
A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)
Vaccine. 2021 Sep 7:S0264-410X(21)01097-5. doi: 10.1016/j.vaccine.2021.08.049. Online ahead of print.ABSTRACTBACKGROUND: Pneumococcal conjugate vaccines (PCVs) have greatly reduced the incidence of pneumococcal disease, yet unmet medical need remains due to increased disease caused by non-vaccine serotypes (STs). V114 (VAXNEUVANCETM, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA) is a 15-valent PCV containing 13 serotypes in licensed PCV13 and 2 additional serotypes (22F, 33F) which significantly contribute to pneumococcal disease burden. This phase 3 trial compared safety, toler...
Source: Vaccine - September 11, 2021 Category: Allergy & Immunology Authors: Heather L Platt Jose F Cardona Miwa Haranaka Howard I Schwartz Silvia Narejos Perez Anthony Dowell Chih-Jen Chang Ron Dagan Gretchen M Tamms Tina Sterling Leslie Morgan Yaru Shi Alison Pedley Luwy K Musey Ulrike K Buchwald Source Type: research
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)
CONCLUSION: Administration of V114 followed by PPSV23 was well tolerated and induced comparable antibody levels to PCV13 followed by PPSV23 in healthy adults aged ≥50 years.PMID:34489128 | DOI:10.1016/j.vaccine.2021.08.038
Source: Vaccine - September 7, 2021 Category: Allergy & Immunology Authors: Joon-Young Song Chih-Jen Chang Charles Andrews Javier Diez-Domingo Myoung-Don Oh Ron Dagan Jonathan Hartzel Alison Pedley Jianing Li Tina Sterling Gretchen Tamms Joseph A Chiarappa Jeannine Lutkiewicz Luwy Musey Yingmei Tu Ulrike K Buchwald V114-016 (PNEU Source Type: research
A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India
CONCLUSION: PCV13 vaccination was well tolerated with an acceptable safety profile in healthy subjects aged 6 to 17 years in India. This work further supports the safety profile of PCV13 for prevention of pneumococcal disease in this age group in India.PMID:34366142 | DOI:10.1016/j.vaccine.2021.07.055
Source: Vaccine - August 9, 2021 Category: Allergy & Immunology Authors: Jugesh Chhatwal Amita Sapru Balasubramanian Sundaram Bhaskar Shenoy Rohit Chand Kevin Yi Suresh Suroju Daniel A Scott Stephen Lockhart Source Type: research
Analysis of two non-pharmacological pain management methods for vaccine injection pain in infants: A randomized controlled trial
CONCLUSION: Local cold and heat application methods applied to the vaccination area before a pneumoccal vaccine reduced vaccine-associated pain in the infants, and the application of cold was more effective than heat.PMID:34254654 | DOI:10.14744/agri.2020.54289
Source: Agri Dergisi - July 13, 2021 Category: Anesthesiology Authors: Tu ğba Güngör Özlem Öztürk Şahin Source Type: research
